Small-cap stocks often fly under Wall Street’s radar, offering early-movers a chance to gain an edge. But the lack of analyst coverage can also mask deeper risks, from weaker balance sheets to limited market share. Here’s a look at one small-cap worth serious consideration—and two that raise red flags.
Despite a price target cut from Chardan, Iovance Biotherapeutics (IOVA) continues to attract attention as one of the most shorted small-cap stocks. The company's first-quarter results, driven by its TIL therapy Amtagvi, surpassed expectations, and its full-year guidance remains robust.
The S&P/ASX Small Ordinaries Index extended its rally, rising 2.28% on Friday to close at 3,501.80 and gaining 2.19% over the past five sessions, as investors rotated back into growth-oriented small caps. A flurry of corporate announcements from ASX-listed companies this morning — spanning debt financing, clinical data, commercial partnerships and leadership changes — is expected to sustain the sector’s upward trajectory.
With strong earnings growth, insider buying, and a solid balance sheet, this Singapore-listed construction and engineering firm is catching the eye of value-focused investors.
